Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma

Clinical trial NCT07701681 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07701681
Sponsor: Sun Yat-sen University
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

ESCC Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Esophageal Squamous Cell Carcinoma (ESCC)GC/GEJC

Start date: 2026-08-31
Primary completion: 2028-09-01
Enrollment: 75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.